Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 65 | SFEBES2019 | Next issue

Society for Endocrinology BES 2019

Brighton, United Kingdom
11 Nov 2019 - 13 Nov 2019

Card image cap
Come and exchange knowledge, share experiences and strengthen collaborations across our global community of endocrinologists!

HOW DO I? SESSIONS

How do I. . .? 2

Previous section
How do I. . .? 1
Table of contents

ea0065hdi2.1 | How do I. . .? 2 | SFEBES2019

Abstract unavailable...
0 shares

ea0065hdi2.2 | How do I. . .? 2 | SFEBES2019

Abstract unavailable...
0 shares

ea0065hdi2.3 | How do I. . .? 2 | SFEBES2019

Abstract unavailable...
0 shares

ea0065hdi2.4 | How do I. . .? 2 | SFEBES2019

How do I decide when to initiate dopamine agonist withdrawal?

Karavitaki Niki

Dopamine agonists (DA) are the first line treatment for patients with symptomatic prolactinoma and aims to lower prolactin, reduce adenoma size and restore gonadal function. This treatment is effective in the majority of patients and DA resistance s reported in around 10% of patients on cabergoline and 20–30% of those on bromocriptine. Established consensus on the optimal duration of DA therapy is lacking. Given the potential adverse effects of DAs in the...
0 shares

ea0065hdi2.5 | How do I. . .? 2 | SFEBES2019

Abstract unavailable...
0 shares

ea0065hdi2.6 | How do I. . .? 2 | SFEBES2019

Abstract unavailable...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more